Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma

S. K. Kumar, E. Ma, A. E. Engebretson, F. K. Buadi, M. Q. Lacy, A. Dispenzieri, M. S. Duh, M. H. Lafeuille, P. Lefebvre, W. Y. Cheng, K. Dea, D. Rembert, D. Patt, L. Niculescu, M. Quick, S. V. Rajkumar

Research output: Contribution to journal › Letter › peer-review

11 Scopus citations

Fingerprint

Dive into the research topics of 'Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma'. Together they form a unique fingerprint.